Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes

Zhang,Wei; Xie,Xinyan; Mi,Huijing; Sun,Jinwan; Ding,Shaoxue; Li,Lijuan; Liu,Hui; Wang,Huaquan; Fu,Rong; Shao,Zonghong

doi:10.3892/ol.2018.8062

Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes

Authors:
- Wei Zhang
- Xinyan Xie
- Huijing Mi
- Jinwan Sun
- Shaoxue Ding
- Lijuan Li
- Hui Liu
- Huaquan Wang
- Rong Fu
- Zonghong Shao
View Affiliations

Affiliations: Department of Hematology, General Hospital of Tianjin Medical University, Heping, Tianjin 300052, P.R. China
Published online on: February 15, 2018 https://doi.org/10.3892/ol.2018.8062
Pages: 5497-5504
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by ineffective hematopoiesis that lead to leukemia. Disorders of the immune system serve important functions in the pathophysiology and progression of this disease. Different levels or mechanisms of natural killer (NK) cells in patients with MDS have been measured in previous studies, making it challenging to understand the pathogenesis of NK cytotoxicity. The present study investigated the frequency of NK cell‑mediated antibody‑dependent cellular cytotoxicity and explored the function of NK cells by their activating receptors, inhibition signals, degranulation and cytotoxicity factors. In the present study, levels of cluster of differentiation (CD)3‑CD56+ NK cells, CD16+‑expressing NK cells and subset CD56dim NK cells were decreased in the peripheral blood of patients with MDS. Altered expression of NK protein 44, NK group 2 member D, killer cell immunoglobulin‑like receptor 2DL1 (KIR2DL1) and KIR2DL3 on NK cell effector signaling pathways may trigger tumor cell lysis in patients with MDS. The weak cellular adhesion and decreased cytotoxicity of NK cells may lead to ineffective antitumor activity in MDS. These observations suggested that NK cells may serve as immunological determinants in MDS and may permit the development of NK cell‑based immunotherapy for the treatment of patients with MDS.

View Figures

View References

1	Adès L, Itzykson R and Fenaux P: Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar : PubMed/NCBI
2	Tefferi A and Vardiman JW: Myelodysplastic syndromes. N Engl J Med. 361:1872–1885. 2009. View Article : Google Scholar : PubMed/NCBI
3	Alfinito F, Sica M, Luciano L, Della Pepa R, Palladino C, Ferrara I, Giani U, Ruggiero G and Terrazzano G: Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol. 148:90–98. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, Lombardi G, Wlodarski MW, Maciejewski JP, Farzaneh F and Mufti GJ: CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 110:847–850. 2007. View Article : Google Scholar : PubMed/NCBI
5	Caligiuri MA: Human natural killer cells. Blood. 112:461–469. 2008. View Article : Google Scholar : PubMed/NCBI
6	Hejazi M, Manser AR, Frobel J, Kündgen A, Zhao X, Schönberg K, Germing U, Haas R, Gattermann N and Uhrberg M: Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. Haematologica. 100:643–652. 2015. View Article : Google Scholar : PubMed/NCBI
7	Chamuleau ME, Westers TM, van Dreunen L, Groenland J, Zevenbergen A, Eeltink CM, Ossenkoppele GJ and van de Loosdrecht AA: Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica. 94:496–506. 2009. View Article : Google Scholar : PubMed/NCBI
8	Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, et al: Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 109:4816–4824. 2007. View Article : Google Scholar : PubMed/NCBI
9	Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
10	Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
11	Kogure T, Fujinaga H, Niizawa A, Hai LX, Shimada Y, Ochiai H and Terasawa K: Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2, but not interferon-gamma or interleukin-4. Mediators Inflamm. 8:313–318. 1999. View Article : Google Scholar : PubMed/NCBI
12	El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, et al: The requirement for DNAM-1, NKG2D and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 67:8444–8449. 2007. View Article : Google Scholar : PubMed/NCBI
13	Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debré P and Vieillard V: Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood. 122:2935–2942. 2013. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL and Phillips JH: DNAM-1, a novel adhesion molecule involved in the cytolytic function of t lymphocytes. Immunity. 4:573–581. 1996. View Article : Google Scholar : PubMed/NCBI
16	Carlsten M, Baumann BC, Simonsson M, Jädersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellström-Lindberg E and Malmberg KJ: Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia. 24:1607–1616. 2010. View Article : Google Scholar : PubMed/NCBI
17	Schlegel P, Ditthard K, Lang P, Mezger M, Michaelis S, Handgretinger R and Pfeiffer M: NKG2D signaling leads to NK cell mediated lysis of childhood AML. J Immunol Res. 2015:4731752015. View Article : Google Scholar : PubMed/NCBI
18	Konjević G, Mirjacić Martinović K, Jurisić V, Babović N and Spuzić I: Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers. 14:258–270. 2009. View Article : Google Scholar : PubMed/NCBI
19	Battella S, Cox MC, Santoni A and Palmieri G: Natural killer (NK) cells and anti-tumor therapeutic mAb: Unexplored interactions. J Leukoc Biol. 99:87–96. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ebert LM, Meuter S and Moser B: Homing and function of human skin gammadelta T cells and NK cells: Relevance for tumor surveillance. J Immunol. 176:4331–4336. 2006. View Article : Google Scholar : PubMed/NCBI
21	Aggarwal N, Swerdlow SH, TenEyck SP, Boyiadzis M and Felgar RE: Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes. Cytometry B Clin Cytom. 90:349–357. 2016. View Article : Google Scholar : PubMed/NCBI
22	Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE and Caligiuri MA: Human natural killer cells: A unique innate immunoregulatory role for the CD56 (bright) subset. Blood. 97:3146–3151. 2001. View Article : Google Scholar : PubMed/NCBI
23	Bryceson YT, March ME, Ljunggren HG and Long EO: Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 214:73–91. 2006. View Article : Google Scholar : PubMed/NCBI
24	Vivier E, Nunès JA and Vély F: Natural killer cell signaling pathways. Science. 306:1517–1519. 2004. View Article : Google Scholar : PubMed/NCBI
25	Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
26	Bachanova V and Miller JS: NK cells in therapy of cancer. Crit Rev Oncog. 19:133–141. 2014. View Article : Google Scholar : PubMed/NCBI